Literature DB >> 16672141

Should we employ combination ACEI and ARB therapy in primary hypertension?

Robert M Carey1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16672141     DOI： 10.1007/s11906-006-0002-2

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  23 in total

Review 1.  Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age.

Authors:  Robert M Carey
Journal:  Hypertension       Date:  2005-02-28       Impact factor: 10.190

Review 2.  Primary and secondary prevention of chronic kidney disease.

Authors:  Kambiz Zandi-Nejad; Barry M Brenner
Journal:  J Hypertens       Date:  2005-10       Impact factor: 4.844

3.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group.

Authors:  K Swedberg; P Eneroth; J Kjekshus; L Wilhelmsen
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

Review 4.  Candesartan cilexetil in cardiovascular disease.

Authors:  Amy Ross; Vasilios Papademetriou
Journal:  Expert Rev Cardiovasc Ther       Date:  2004-11

5.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.

Authors:  C E Mogensen; S Neldam; I Tikkanen; S Oren; R Viskoper; R W Watts; M E Cooper
Journal:  BMJ       Date:  2000-12-09

6.  Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.

Authors:  Peter Jacobsen; Steen Andersen; Kasper Rossing; Birgitte V Hansen; Hans-Henrik Parving
Journal:  Nephrol Dial Transplant       Date:  2002-06       Impact factor: 5.992

7.  Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.

Authors:  James B Young; Mark E Dunlap; Marc A Pfeffer; Jeffrey L Probstfield; Alain Cohen-Solal; Rainer Dietz; Christopher B Granger; Jaromir Hradec; Jerzy Kuch; Robert S McKelvie; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Peter Held; Scott D Solomon; Salim Yusuf; Karl Swedberg
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

Review 8.  Pathologic consequences of increased angiotensin II activity.

Authors:  C M Ferrario; J M Flack
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

9.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

Authors:  Naoyuki Nakao; Ashio Yoshimura; Hiroyuki Morita; Masyuki Takada; Tsuguo Kayano; Terukuni Ideura
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

10.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.